Adzenys Med Info
- Kevin Keane
- Aug 13, 2024
- 3 min read
Updated: Aug 15, 2024
Adzenys XR-ODT is a prescription medication approved by the FDA for treating Attention Deficit Hyperactivity Disorder (ADHD) in individuals aged 6 years and older. As a central nervous system (CNS) stimulant, Adzenys works by increasing the activity of certain chemicals in the brain, which helps improve focus, reduce impulsivity, and manage hyperactivity.
What Makes Adzenys XR-ODT Unique?
Chemically, Adzenys XR-ODT is equivalent to Adderall XR, another well-known ADHD medication. However, Adzenys XR-ODT uses a unique orally disintegrating tablet (ODT) technology, which allows the medication to dissolve in the mouth without water. This is particularly helpful for individuals who have difficulty swallowing pills. The medication is delivered through microparticle technology, ensuring that the effects last throughout the day, typically between 8 to 12 hours, similar to Adderall XR.
When and How to Take Adzenys XR-ODT
Adzenys XR-ODT is designed to be taken once daily in the morning, ideally with or after breakfast. Taking it in the morning helps to minimize any potential impact on appetite, as stimulants like Adzenys can suppress hunger. This extended-release formulation is favored for managing ADHD because it provides steady symptom control throughout the day with fewer side effects compared to immediate-release formulations.
How Adzenys XR-ODT Works
Adzenys XR-ODT is composed of thousands of microparticles, with half providing immediate release and the other half providing extended release. This dual-action ensures that the medication is effective both in the morning and later in the day. The active ingredient, amphetamine, increases the levels of norepinephrine and dopamine in the brain by blocking their reuptake and enhancing their release. These neurotransmitters play key roles in improving attention, concentration, executive functioning, and reducing hyperactivity.
Dosing Information
The dosing of Adzenys XR-ODT differs slightly from Adderall XR because it doesn’t contain amphetamine salts or fillers. Despite this difference, the effects of Adzenys XR-ODT are comparable in onset, peak, and duration to Adderall XR. Doses range from 3.1 mg (similar to 5 mg of Adderall XR) to a maximum of 18.8 mg per day (comparable to 30 mg of Adderall XR). Your healthcare provider will work with you to determine the appropriate dose based on your specific needs.
Why Choose Adzenys XR-ODT?
One of the key advantages of Adzenys XR-ODT is its ease of administration. The tablet dissolves in the mouth, making it a great option for those who find it challenging to swallow traditional pills or capsules. Additionally, Adzenys XR-ODT is a brand-name medication that offers a savings program, potentially lowering the cost to as little as $50 with commercial insurance, even if the insurance provider doesn’t cover the medication. It also offers the convenience of direct, free shipping.
Potential Side Effects
As with all stimulant medications, it’s important to monitor for side effects. While stimulants are generally safe, especially when used as directed, there are a few common side effects to be aware of:
Appetite suppression: Can lead to weight loss if not monitored.
Irritability: Especially as the medication wears off.
Anxiety and insomnia: More likely if taken later in the day.
Tics: Motor or verbal tics, particularly in younger boys.
It’s also important to exercise caution in individuals with a family history of cardiac issues, as stimulants can affect the heart similarly to high doses of caffeine.
Conclusion
Adzenys XR-ODT is a highly effective and well-tolerated option for managing ADHD symptoms. Its unique orally disintegrating formulation and extended-release action make it a convenient and reliable choice for individuals seeking consistent symptom control throughout the day. As with any medication, regular follow-up with your healthcare provider is essential to ensure that the treatment is working effectively and to monitor for any potential side effects.
Written by:
Joseph Gagnon Jr.